Heron Therapeutics Inc Financials
Heron Therapeutics Inc (HRTX) reported $154.9M in revenue for fiscal year 2025, up 7.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Gross-margin reset and a lighter R&D load have nearly erased the operating loss, while working capital still absorbs cash.
Over the last two years, gross margin moved from48.8% to73.3% , and that step-up did most of the work in shrinking the operating loss. Yet cash conversion still lags because inventory and receivables reached$182.3M , while interest expense rose to$9.6M ; the business is much closer to operating break-even than to balance-sheet ease.
This no longer looks like a company dominated by research spend: R&D fell from
The balance sheet is still thinly capitalized: equity is only
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Heron Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Heron Therapeutics Inc, and counted as zero in the overall score.
Not available for Heron Therapeutics Inc, and counted as zero in the overall score.
Heron Therapeutics Inc scores -9.23, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($59.3M) relative to total liabilities ($241.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Heron Therapeutics Inc passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Heron Therapeutics Inc reported a net loss of $20.0M while operations used $27.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Heron Therapeutics Inc reported an operating loss of $2.5M against $9.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Heron Therapeutics Inc generated $154.9M in revenue in fiscal year 2025. This represents an increase of 7.4% from the prior year.
Heron Therapeutics Inc's EBITDA was -$224K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 97.5% from the prior year.
Heron Therapeutics Inc reported -$20.0M in net income in fiscal year 2025. This represents a decrease of 42.9% from the prior year.
Heron Therapeutics Inc earned -$0.12 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 33.3% from the prior year.
Cash & Balance Sheet
Heron Therapeutics Inc recorded an outflow of $27.9M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 15.2% from the prior year.
Heron Therapeutics Inc held $28.6M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Heron Therapeutics Inc's gross margin was 73.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.1 percentage points from the prior year.
Heron Therapeutics Inc's operating margin was -1.6% in fiscal year 2025, reflecting core business profitability. This is up 6.3 percentage points from the prior year.
Heron Therapeutics Inc's net profit margin was -12.9% in fiscal year 2025, showing the share of revenue converted to profit. This is down 3.2 percentage points from the prior year.
Heron Therapeutics Inc's ROE was -139.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
Heron Therapeutics Inc invested $12.4M in research and development in fiscal year 2025. This represents a decrease of 25.5% from the prior year.
Heron Therapeutics Inc invested $317K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 81.4% from the prior year.
Not reported for fiscal year 2025.
HRTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $151.2M | $154.9M+7.4% | $144.3M+13.6% | $127.0M+18.0% | $107.7M+24.7% | $86.3M-2.6% | $88.6M-39.3% | $146.0M+88.4% | $77.5M+151.8% | $30.8M+2305.6% | $1.3M | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | $45.2M | $41.3M+7.0% | $38.6M-40.6% | $65.1M+18.6% | $54.9M+19.2% | $46.0M+27.2% | $36.2M-41.3% | $61.6M+124.0% | $27.5M+499.7% | $4.6M+13008.6% | $35K | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $105.9M | $113.6M+7.5% | $105.6M+70.6% | $61.9M+17.3% | $52.8M+30.9% | $40.3M-23.1% | $52.4M-37.8% | $84.3M+68.8% | $50.0M+90.8% | $26.2M+2004.4% | $1.2M | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $12.3M | $12.4M-25.5% | $16.7M-57.4% | $39.1M-52.7% | $82.7M-36.8% | $130.8M-25.0% | $174.5M+4.3% | $167.4M+19.5% | $140.0M+1.0% | $138.6M+34.4% | $103.1M+68.6% | $61.2M+11.6% | $54.8M+68.6% | $32.5M+114.3% | $15.2M+84.9% | $8.2M |
| SG&A Expenses | $50.9M | $54.6M+2.3% | $53.4M-18.8% | $65.8M+5.7% | $62.2M+55.0% | $40.2M-4.9% | $42.2M+11.4% | $37.9M+29.5% | $29.3M+14.5% | $25.6M+19.6% | $21.4M+16.2% | $18.4M+66.9% | $11.0M-49.8% | $21.9M+153.4% | $8.7M+147.3% | $3.5M |
| Operating Income | -$10.9M | -$2.5M+78.0% | -$11.5M+89.6% | -$110.6M+36.7% | -$174.7M+19.8% | -$217.8M+4.5% | -$228.2M-8.3% | -$210.7M-14.5% | -$183.9M+5.5% | -$194.6M-13.8% | -$170.9M-76.3% | -$96.9M-30.0% | -$74.6M-36.9% | -$54.5M-128.5% | -$23.8M-115.4% | -$11.1M |
| Interest Expense | N/A | $9.6M+59.2% | $6.0M+55.9% | $3.9M+56.3% | $2.5M+2.7% | $2.4M+26.8% | $1.9M+29.1% | $1.5M-44.9% | $2.7M-32.1% | $3.9M+47.8% | $2.7M+178.1% | $958K+8.0% | $887K+7.1% | $828K+36.9% | $605K | N/A |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$33.9M | -$20.0M-42.9% | -$14.0M+87.4% | -$111.0M+39.0% | -$182.0M+17.6% | -$221.0M+2.8% | -$227.3M-11.0% | -$204.7M-14.5% | -$178.8M+9.4% | -$197.5M-14.1% | -$173.1M-77.4% | -$97.6M-27.8% | -$76.4M-38.1% | -$55.3M-136.8% | -$23.3M-97.6% | -$11.8M |
| EPS (Diluted) | — | -$0.12-33.3% | -$0.09+88.8% | -$0.80+52.1% | -$1.67+25.4% | -$2.24 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
HRTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $255.9M+9.7% | $233.1M+4.8% | $222.5M-11.3% | $251.0M-17.9% | $305.7M-13.5% | $353.6M-31.1% | $512.8M+10.9% | $462.2M+97.3% | $234.3M+247.2% | $67.5M-51.0% | $137.8M+79.8% | $76.7M+1.0% | $75.9M+35.7% | $56.0M+187.8% | $19.4M |
| Current Assets | $238.1M+13.9% | $209.0M+10.7% | $188.8M-8.1% | $205.4M-19.3% | $254.4M-19.0% | $314.2M-34.4% | $479.1M+7.1% | $447.2M+96.1% | $228.1M+267.0% | $62.1M-53.9% | $134.8M+82.8% | $73.7M+1.1% | $72.9M+34.8% | $54.1M+196.5% | $18.2M |
| Cash & Equivalents | $28.6M+11.0% | $25.8M-10.0% | $28.7M+86.7% | $15.4M-83.0% | $90.5M-13.9% | $105.1M+46.2% | $71.9M+125.8% | $31.8M-78.0% | $144.6M+977.9% | $13.4M-82.2% | $75.2M+3.4% | $72.7M+0.5% | $72.3M+35.1% | $53.5M+197.7% | $18.0M |
| Inventory | $92.7M+74.5% | $53.2M+26.2% | $42.1M-22.8% | $54.6M+12.8% | $48.4M+15.5% | $41.9M+67.8% | $25.0M-36.0% | $39.0M+286.1% | $10.1M+89.3% | $5.3M | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $89.6M+13.6% | $78.9M+31.2% | $60.1M+15.5% | $52.0M+46.6% | $35.5M-15.2% | $41.9M+4.9% | $39.9M-38.3% | $64.7M+54.4% | $41.9M+2036.4% | $2.0M | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $241.5M-9.5% | $266.8M+4.0% | $256.5M+8.0% | $237.4M+4.1% | $228.1M+94.9% | $117.1M+7.5% | $108.9M+18.4% | $92.0M-10.8% | $103.2M+16.3% | $88.7M+349.6% | $19.7M+44.9% | $13.6M+94.8% | $7.0M+68.3% | $4.2M+12.5% | $3.7M |
| Current Liabilities | $96.1M+5.1% | $91.5M+14.8% | $79.7M-3.2% | $82.4M+15.9% | $71.1M-30.7% | $102.5M+6.0% | $96.7M+5.1% | $92.0M-10.8% | $103.2M+166.4% | $38.7M+96.3% | $19.7M+44.9% | $13.6M+94.8% | $7.0M+68.3% | $4.2M+12.5% | $3.7M |
| Total Equity | $14.3M+142.6% | -$33.7M+0.9% | -$34.0M-350.3% | $13.6M-82.5% | $77.6M-67.2% | $236.5M-41.4% | $403.8M+9.1% | $370.2M+182.3% | $131.1M+717.1% | -$21.3M-118.0% | $118.1M+87.3% | $63.1M-8.5% | $68.9M+33.1% | $51.8M+229.0% | $15.8M |
| Retained Earnings | -$1.9B-1.1% | -$1.9B-0.7% | -$1.9B-6.2% | -$1.8B-11.3% | -$1.6B-15.8% | -$1.4B-19.5% | -$1.2B-21.3% | -$960.7M-22.6% | -$783.5M-33.7% | -$586.0M-41.9% | -$412.8M-31.0% | -$315.2M-32.0% | -$238.9M-30.1% | -$183.6M-14.6% | -$160.2M |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
HRTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$11.6M | -$27.6M-22.5% | -$22.5M+61.7% | -$58.8M+60.0% | -$146.9M+27.8% | -$203.4M-10.0% | -$184.8M-48.4% | -$124.6M+35.0% | -$191.8M-12.6% | -$170.3M-27.0% | -$134.1M-70.8% | -$78.5M-30.3% | -$60.3M-47.9% | -$40.8M-139.7% | -$17.0M-120.3% | -$7.7M |
| Capital Expenditures | $529K | $317K-81.4% | $1.7M+10.4% | $1.5M-15.3% | $1.8M-39.6% | $3.0M-55.6% | $6.8M-4.8% | $7.2M-22.0% | $9.2M+259.2% | $2.6M-18.6% | $3.1M+188.7% | $1.1M-24.5% | $1.4M-14.7% | $1.7M+73.4% | $972K+89.5% | $513K |
| Free Cash Flow | -$12.1M | -$27.9M-15.2% | -$24.2M+59.8% | -$60.3M+59.4% | -$148.7M+27.9% | -$206.4M-7.7% | -$191.6M-45.5% | -$131.7M+34.5% | -$201.0M-16.3% | -$172.9M-26.0% | -$137.2M-72.4% | -$79.6M-29.0% | -$61.7M-45.4% | -$42.4M-136.1% | -$18.0M-118.4% | -$8.2M |
| Investing Cash Flow | $2.2M | $16.0M-14.5% | $18.7M+4.0% | $18.0M+641.4% | -$3.3M-110.2% | $32.7M-84.3% | $209.0M+1059.3% | -$21.8M+92.2% | -$278.6M-3699.8% | $7.7M-48.0% | $14.9M+126.1% | -$57.0M-3861.1% | -$1.4M+14.7% | -$1.7M-73.4% | -$972K-89.5% | -$513K |
| Financing Cash Flow | $13.6M | $14.4M+1434.8% | $940K-98.3% | $54.1M-27.9% | $75.1M-51.9% | $156.0M+1613.7% | $9.1M-95.1% | $186.4M-47.9% | $357.6M+21.7% | $293.7M+411.2% | $57.5M-58.4% | $138.0M+122.2% | $62.1M+1.4% | $61.2M+14.4% | $53.5M+122.1% | $24.1M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
HRTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 73.3%+0.1pp | 73.2%+24.5pp | 48.8%-0.3pp | 49.0%+2.3pp | 46.7%-12.5pp | 59.2%+1.4pp | 57.8%-6.7pp | 64.5%-20.6pp | 85.1%-12.2pp | 97.3% | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -1.6%+6.3pp | -8.0%+79.1pp | -87.1% | -162.2% | -252.3% | -257.4% | -144.3% | -237.4% | -632.4% | -13363.2% | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -12.9%-3.2pp | -9.7%+77.7pp | -87.4% | -169.0% | -255.9% | -256.4% | -140.3% | -230.8% | -641.9% | -13537.4% | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -139.5% | N/A | N/A | -1341.0%-1056.1pp | -284.9%-188.8pp | -96.1%-45.4pp | -50.7%-2.4pp | -48.3%+102.3pp | -150.6% | N/A | -82.6%+38.5pp | -121.1%-40.9pp | -80.2%-35.1pp | -45.1%+29.9pp | -75.0% |
| Return on Assets | -7.8%-1.8pp | -6.0%+43.9pp | -49.9%+22.6pp | -72.5%-0.2pp | -72.3%-8.0pp | -64.3%-24.4pp | -39.9%-1.2pp | -38.7%+45.6pp | -84.3%+172.3pp | -256.6%-185.8pp | -70.8%+28.8pp | -99.6%-26.8pp | -72.8%-31.1pp | -41.7%+19.1pp | -60.8% |
| Current Ratio | 2.48+0.2x | 2.29-0.1x | 2.37-0.1x | 2.49-1.1x | 3.58+0.5x | 3.07-1.9x | 4.95+0.1x | 4.86+2.6x | 2.21+0.6x | 1.60-5.2x | 6.83+1.4x | 5.41-5.0x | 10.43-2.6x | 13.02+8.1x | 4.94 |
| Debt-to-Equity | 16.85 | N/A | N/A | 17.49+14.5x | 2.94+2.4x | 0.49+0.2x | 0.270.0x | 0.25-0.5x | 0.79 | N/A | 0.170.0x | 0.22+0.1x | 0.100.0x | 0.08-0.2x | 0.23 |
| FCF Margin | -18.0%-1.2pp | -16.8%+30.7pp | -47.5% | -138.1% | -239.0% | -216.2% | -90.3% | -259.4% | -561.8% | -10729.6% | N/A | N/A | N/A | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Heron Therapeutics Inc Ranks
Frequently Asked Questions
What is Heron Therapeutics Inc's annual revenue?
Heron Therapeutics Inc (HRTX) reported $154.9M in total revenue for fiscal year 2025. This represents a 7.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Heron Therapeutics Inc's revenue growing?
Heron Therapeutics Inc (HRTX) revenue grew by 7.4% year-over-year, from $144.3M to $154.9M in fiscal year 2025.
Is Heron Therapeutics Inc profitable?
No, Heron Therapeutics Inc (HRTX) reported a net income of -$20.0M in fiscal year 2025, with a net profit margin of -12.9%.
What is Heron Therapeutics Inc's EBITDA?
Heron Therapeutics Inc (HRTX) had EBITDA of -$224K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Heron Therapeutics Inc's gross margin?
Heron Therapeutics Inc (HRTX) had a gross margin of 73.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Heron Therapeutics Inc's operating margin?
Heron Therapeutics Inc (HRTX) had an operating margin of -1.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Heron Therapeutics Inc's net profit margin?
Heron Therapeutics Inc (HRTX) had a net profit margin of -12.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Heron Therapeutics Inc's return on equity (ROE)?
Heron Therapeutics Inc (HRTX) has a return on equity of -139.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Heron Therapeutics Inc's free cash flow?
Heron Therapeutics Inc (HRTX) recorded an outflow of $27.9M in free cash flow during fiscal year 2025. This represents a -15.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Heron Therapeutics Inc's operating cash flow?
Heron Therapeutics Inc (HRTX) recorded an outflow of $27.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Heron Therapeutics Inc's total assets?
Heron Therapeutics Inc (HRTX) had $255.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Heron Therapeutics Inc's capital expenditures?
Heron Therapeutics Inc (HRTX) invested $317K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Heron Therapeutics Inc spend on research and development?
Heron Therapeutics Inc (HRTX) invested $12.4M in research and development during fiscal year 2025.
What is Heron Therapeutics Inc's current ratio?
Heron Therapeutics Inc (HRTX) had a current ratio of 2.48 as of fiscal year 2025, which is generally considered healthy.
What is Heron Therapeutics Inc's debt-to-equity ratio?
Heron Therapeutics Inc (HRTX) had a debt-to-equity ratio of 16.85 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Heron Therapeutics Inc's return on assets (ROA)?
Heron Therapeutics Inc (HRTX) had a return on assets of -7.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Heron Therapeutics Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Heron Therapeutics Inc (HRTX) held $46.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $27.6M over that year. Dividing the one by the other, the reported balance equals about 20 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Heron Therapeutics Inc's Altman Z-Score?
Heron Therapeutics Inc (HRTX) has an Altman Z-Score of -9.23, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Heron Therapeutics Inc's Piotroski F-Score?
Heron Therapeutics Inc (HRTX) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Heron Therapeutics Inc's earnings high quality?
Heron Therapeutics Inc (HRTX) reported a net loss of $20.0M while operations used $27.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Heron Therapeutics Inc cover its interest payments?
Heron Therapeutics Inc (HRTX) reported an operating loss of $2.5M against $9.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Heron Therapeutics Inc?
Heron Therapeutics Inc (HRTX) scores 34 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.